of preclinical and clinical
studies, the research work enabled to develop the
original solvent for poorly soluble
Zelinska, N.,
Iotova, V.,
Skorodok, J.,
Malievsky, O.,
Peterkova, V.,
Samsonova, L.,
Rosenfeld, Ron G.,
Zadik, Zvi,
Jaron-Mendelson, Michal,
Koren, Ronit,
Amitzi, Leanne,
Raduk, Dmitri,
Hershkovitz, Oren,
Hart, Gili (2017) and children. The present trial was a safety and
dose-finding
study for weekly MOD-4023 in GHD children.
Design
. According to epidemiological
studies, at least once during a lifetime this pathology is observed in 15
Kayumova, R.R.,
Sultanbaev, A.V.,
Ostakhov, S.S.,
Khursan, S.L.,
Abdullin, M.F.,
Gantsev, S.K.,
Sakaeva, D.D. (2017) THE «IN VIVO»
STUDY OF BLOOD 5-FLUOROURACIL CONTENT BY QUENCHING OF INTRINSIC PROTEIN FLUORESCENCE
and flow of chronic
recurrent dermatoses, including lichen planus in oral mucosa, is
studied. To
studyДьяконов, В.А.,
Джемилева, Л.У.,
Джемилев, У.М.,
D'yakonov, V.A.,
Dzhemileva, L.U.,
Dzhemilev, U.M. (2017) studies in this field have shown that topoisomerases I and II are one of the main molecular targets
Chatelain, Pierre,
Malievskiy, Oleg,
Radziuk, Klaudziya,
Senatorova, Ganna,
Abdou, Magdy O.,
Vlachopapadopoulou, Elpis,
Skorodok, Yulia,
Peterkova, Valentina,
Leff, Jonathan A.,
Beckert, Michael (2017) children with GHD.
Design: Randomized, open-label, active-controlled
study of three doses of weekly Trans
The review presents the data of recent
studies dealing with cognitive impairments (CI) in patients